ReviewNature clinical practice. Nephrology2009
Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?
Review in Nature clinical practice. Nephrology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020Trial
- Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.Clinical journal of the American Society of Nephrology : CJASN · 2011Trial
- Combination therapy with nutritional vitamin D and calcimimetics in secondary hyperparathyroidism: a mechanism-based approach to restoring PTH regulation.Frontiers in nutrition · 2026Review
- Fragility Fractures in End-Stage Chronic Kidney Disease (CKD) Population: Patient-Related and CKD-Related Factor Analysis-A Single-Center Experience.Journal of clinical medicine · 2024Article
- Article
- Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.Pediatric nephrology (Berlin, Germany) · 2020Review
- Refractory hypercalcemia due to an ectopic mediastinal parathyroid gland in a hemodialysis patient: a case report.BMC nephrology · 2019Article
- The role of hormones in renal disease and ischemia-reperfusion injury.Iranian journal of basic medical sciences · 2019Review
- Management and outcomes of hyperparathyroidism: a case series from a single institution over two decades.Therapeutics and clinical risk management · 2018Article
- Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study.Wiener klinische Wochenschrift · 2017Observational
- A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument.International urology and nephrology · 2017Review
- A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia.Science signaling · 2016Article
- Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis.Systematic reviews · 2016Article
- Molecular basis of Klotho: from gene to function in aging.Endocrine reviews · 2015Review
- Treatment of phosphate retention: The earlier the better?Kidney research and clinical practice · 2014Review
- A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease.Seminars in nephrology · 2013Review
- Management of natural and added dietary phosphorus burden in kidney disease.Seminars in nephrology · 2013Review
- Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites.Kidney international · 2012Article
- Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.Experimental cell research · 2012Review
- Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.Nature reviews. Endocrinology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Considerable advances have been made in the understanding of the pathogenesis and treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD). These include the discovery that the calcium-sensing receptor has an important role in the regulation of parathyroid gland function, the development of calcimimetics to target this receptor, the recognition that vitamin D receptor activation has important functions beyond the regulation of mineral metabolism, the identification of the phosphaturic factor fibroblast growth factor 23 and the contribution of this hormone to disordered phosphate and vitamin D metabolism in CKD. However, despite the availability of calcimimetics, phosphate binders, and vitamin D analogs, control of SHPT remains suboptimal in many patients with advanced kidney disease. In this Review, we explore several unresolved issues regarding the pathogenesis and treatment of SHPT. Specifically, we examine the significance of elevated circulating fibroblast growth factor 23 levels in CKD, question the proposition that calcitriol deficiency is truly a pathological state, explore the relative importance of the vitamin D receptor and the calcium-sensing receptor in parathyroid gland function and evaluate the evidence to support the treatment of SHPT with calcimimetics and vitamin D analogs. Finally, we propose a novel treatment framework in which calcimimetics are the primary therapy for suppressing parathyroid hormone production in patients with end-stage renal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.